Releviate Therapeutics

Releviate Therapeutics Founded in 2020, Releviate Therapeutics is a biopharmaceutical company dedicated to addressing the needs of patients with chronic pain. Releviate Therapeutics' therapeutic strategy utilizes specific human monoclonal antibodies to inactivate certain matrix metalloproteinases (MMP-9 and MMP-14) and has the potential to improve patient outcomes. Unlike traditional chronic pain medication strategies, Releviate Therapeutics directly targets pain with antibodies, which are generated based on actual pain pathology and directly deactivate pain pathways. The initial indications involve small fiber neuropathy and diabetic neuropathy. Current medications can temporarily and effectively relieve mild pain. Releviate Therapeutics' novel breakthrough technology targets chronic, moderate to severe pain and may offer long-lasting pain relief. The new human antibodies developed by Releviate can fundamentally eliminate target pain: secreted matrix metalloproteinases (MMPs) that cause chronic pain.